Palisade Bio, Inc.
- Open
- 2.08
- Day high
- 2.13
- Day low
- 2.08
- Prev close
- 2.06
- Volume
- 1.1M
- Mkt cap
- $366M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.0
- P/S
- 731.9
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$160K over the last 3 months (6 open-market buys, 2 sales)
- 🏛Institutions reducing (13F)
Palisade Bio, Inc. (PALI) is a Healthcare company listed on NASDAQ. The stock is up 182% over the past year. Over the trailing 3 months, insiders filed 6 open-market buys and 2 sales (SEC Form 4).
Palisade Bio, Inc. (PALI) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PALI earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $-0.05 | $-0.05 | +4.3% | $500000 | +0.0% |
| May 12, 2026 | $-0.04 | $-0.05 | -25.0% | — | — |
| Mar 23, 2026 | $-0.02 | $-0.04 | -100.0% | — | — |
| Mar 24, 2025 | $-1.99 | $-0.69 | +65.3% | $4000 | — |
| Nov 9, 2023 | $-0.39 | $-7.35 | -1784.6% | — | — |
| Aug 11, 2023 | $-0.45 | $-7.95 | -1666.7% | — | — |
| May 12, 2023 | $-0.72 | $-8.10 | -1025.0% | $250000 | — |
| Mar 22, 2023 | $-2.43 | $6.47 | +366.3% | — | — |
| Nov 14, 2022 | $-4.00 | $-59.97 | -1399.3% | — | — |
| Aug 15, 2022 | $-8.50 | $-89.96 | -958.4% | — | — |
| May 13, 2022 | $-210.00 | $-194.90 | +7.2% | — | — |
| Mar 16, 2022 | $-11.75 | $554.72 | +4821.0% | — | — |
PALI insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 10, 2026 | Baltera Robert Jr.director | Buy | 25,000 | $1.96 |
| Jul 10, 2026 | Baltera Robert Jr.director | Buy | 20,000 | $1.99 |
| Jul 8, 2026 | Finley John Daviddirector, officer: CEO, CFO | Option | 133 | $0.70 |
| Jul 8, 2026 | Finley John Daviddirector, officer: CEO, CFO | Sell | 146,798 | $2.07 |
| Jul 8, 2026 | Jones Mitchell Lawrenceofficer: Chief Medical Officer | Sell | 51,880 | $2.05 |
| Jul 8, 2026 | Jones Mitchell Lawrenceofficer: Chief Medical Officer | Option | 131,167 | — |
| Jul 8, 2026 | Finley John Daviddirector, officer: CEO, CFO | Option | 335,167 | — |
| Jul 8, 2026 | Baltera Robert Jr.director | Buy | 30,000 | $2.03 |
| Jul 8, 2026 | Baltera Robert Jr.director | Buy | 20,000 | $2.05 |
| Jul 6, 2026 | Baltera Robert Jr.director | Buy | 20,000 | $1.98 |
| Jul 6, 2026 | Baltera Robert Jr.director | Buy | 10,000 | $1.98 |
| Jun 18, 2026 | Baltera Robert Jr.director | Grant | 336,904 | — |
| Jun 12, 2026 | Zwick Jordan Michaeldirector | Grant | 336,904 | — |
| Jun 12, 2026 | Chuang Emildirector | Grant | 592,300 | — |
| Jun 12, 2026 | Wei Binxiandirector | Option | 20,200 | — |
Source: PALI SEC Form 4 filings, latest Jul 10, 2026. For informational purposes only — not investment advice.
See the full PALI insider & 13F page →Palisade Bio, Inc. company profile
Overview
Palisade Bio, Inc. (NASDAQ:PALI) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Carlsbad, California. The company went public in 2007 and focuses on developing oral therapies designed to protect the gastrointestinal tract's mucosal barrier during periods of intestinal stress. As a pre-revenue biotechnology company, Palisade Bio is currently advancing its lead drug candidate through clinical trials, targeting conditions where the protective lining of the digestive system becomes compromised due to reduced blood flow, infections, or surgical procedures.
Business
Palisade Bio operates in the biotechnology sector, specifically focusing on gastrointestinal therapeutics. The company's core mission centers on addressing a fundamental medical problem: the breakdown of the mucosal barrier that protects the gastrointestinal tract. This protective barrier, which lines the inside of the digestive system, can become damaged during various medical conditions and procedures, leading to serious complications. The company's lead therapeutic candidate is LB1148, an oral liquid formulation containing digestive enzyme inhibitors. To understand what this means, it's important to know that digestive enzymes are proteins that normally help break down food in the intestines. However, during periods of intestinal stress - such as when blood flow to the intestines is reduced (ischemia), during infections, or following surgery - these same enzymes can become harmful and actually damage the intestinal wall itself. LB1148 works by temporarily inhibiting these digestive enzymes, essentially giving the intestinal lining time to heal and maintain its protective function during vulnerable periods. The drug is designed to be taken orally as a liquid, making it easier to administer to patients who may be recovering from surgery or dealing with gastrointestinal distress. The biotechnology industry in which Palisade Bio operates is characterized by high-risk, high-reward drug development processes that can take many years and hundreds of millions of dollars to bring a single therapy to market. Companies in this space typically focus on unmet medical needs where existing treatments are inadequate or non-existent.
Revenue model
As a clinical-stage biopharmaceutical company, Palisade Bio currently generates no meaningful revenue from product sales, as evidenced by zero revenue in most recent quarters (with only $250,000 in revenue reported for 2023, likely from research collaborations or licensing activities). The company's business model is typical of early-stage biotech firms: it relies on raising capital through equity financing and potentially partnerships to fund its research and development activities until its drug candidates can be commercialized. Once LB1148 successfully completes clinical trials and receives regulatory approval, Palisade Bio would generate revenue through pharmaceutical product sales to hospitals, healthcare systems, and potentially direct-to-patient channels. The target market would include patients undergoing gastrointestinal surgery, those with intestinal ischemia, and individuals suffering from conditions that compromise gut barrier function. Several factors could significantly impact the company's future profitability margins. Positive factors include the potential for premium pricing if LB1148 addresses an unmet medical need with limited competition, possible partnership deals with larger pharmaceutical companies that could provide upfront payments and milestone payments, and the relatively straightforward oral delivery method which could reduce manufacturing costs compared to injectable biologics. Negative margin pressures could come from the high cost of clinical trials and regulatory compliance, intense competition from larger pharmaceutical companies with deeper resources, potential pricing pressure from healthcare payers and insurance companies, and the substantial manufacturing and quality control costs required for pharmaceutical production. The company's small size also means it lacks the economies of scale that larger pharmaceutical companies enjoy in manufacturing and distribution.
Competitive moat
Palisade Bio's competitive moat appears relatively limited at this stage of development. The company's primary potential advantage lies in its focused expertise on gastrointestinal mucosal barrier protection and its specific approach using digestive enzyme inhibitors. If LB1148 successfully demonstrates efficacy and safety in clinical trials, the company could establish a first-mover advantage in this particular therapeutic niche. However, the moat is inherently weak for several reasons. The biotechnology industry offers limited patent protection compared to other industries, typically lasting only 20 years from filing date, and much of that time is consumed during the lengthy development and approval process. Additionally, larger pharmaceutical companies with substantially greater resources could potentially develop competing therapies or acquire Palisade Bio if LB1148 shows promise. The company lacks the diversified product portfolio, established distribution networks, and financial resources that create stronger competitive moats for larger pharmaceutical companies. The most significant competitive threats come from well-funded pharmaceutical giants that could enter this therapeutic area, alternative treatment approaches for gastrointestinal protection that might prove more effective or easier to administer, and the general risk that LB1148 may not demonstrate sufficient efficacy or safety in clinical trials. Without a successful product launch and market penetration, Palisade Bio remains vulnerable to competitive displacement and faces the constant risk of clinical trial failure that could eliminate its value proposition entirely.
Risks & safety
The margin of safety for Palisade Bio is concerning, reflecting the high-risk nature of clinical-stage biotechnology investments. • **Cash Position**: The company maintains $7.2 million in cash and short-term investments as of Q1 2025, down from $9.8 million in Q4 2024, indicating rapid cash consumption. • **Burn Rate**: Operating cash flow was negative $2.3 million in Q1 2025 and negative $12.2 million for full year 2024, suggesting approximately 3-4 quarters of remaining runway at current burn rates. • **Debt Level**: Minimal debt with debt-to-equity ratio of only 0.01, indicating low leverage risk. • **Solvency Risk**: High solvency risk due to no revenue generation and significant ongoing cash burn for R&D activities. • **Valuation Metrics**: Trading at 0.61x book value and negative earnings multiples due to losses, suggesting potential value but high uncertainty. • **Other Considerations**: Current ratio of 2.84 provides some short-term liquidity cushion, but the company will likely need additional financing within the next 12 months to continue operations and fund clinical trials.
Recent development
Based on the available financial data, Palisade Bio has maintained a consistent focus on advancing its lead candidate LB1148 through the clinical development process. The company's cash position has steadily declined from $12.4 million at the end of 2023 to $7.2 million in Q1 2025, reflecting ongoing investment in research and development activities. The burn rate has remained relatively stable, with annual operating cash flow losses of approximately $11-12 million, suggesting disciplined spending on core development activities. The company appears to have maintained its strategic focus on gastrointestinal therapeutics without major pivots or diversification into other therapeutic areas. The minimal revenue of $250,000 in 2023 (compared to zero in other periods) suggests possible research collaboration or licensing activities, though these have not developed into sustained revenue streams. The consistent negative EBITDA ranging from $12-15 million annually indicates the company remains in full development mode without any meaningful commercialization activities yet.
PALI company profile · for informational purposes only — not investment advice.
Track PALI with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free